High-affinity t cell receptor targeting ny-ESO-1 and use thereof
By performing affinity maturation screening of 1G4 clones, the affinity of targeting NY-ESO-1 T cell receptors is improved, the problem of insufficient T cell receptor affinity in the prior art is solved, and efficient killing of tumor cells is achieved. Significant anti-tumor activity and clinical value.
Patent Information
- Application Number
- PCT/CN2023/097162
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
The existing T cell receptor targeting NY-ESO-1 has low affinity, resulting in low recognition and killing efficiency for tumor cells. It is necessary to improve the affinity of T cell receptors to improve anti-tumor efficacy.
By performing affinity maturation screening of 1G4 clones, mutation clones were screened to improve the affinity for HLA-A*0201-NY-ESO-1, and high-affinity TCR was developed for TCR-T cell therapy drugs.
It significantly improves the killing efficiency of NY-ESO-1-positive tumor cells, has stronger tumor cell killing ability and anti-tumor activity, and has important clinical value.
Smart Images

Figure CN2023097162_05122024_PF_FP_ABST
Abstract
Description
High-affinity T cell receptor targeting NY-ESO-1 and its application Technical Field
[0001] The present invention relates to the fields of immunology and tumor therapy. Specifically, the present invention relates to a high-affinity T cell receptor (TCR) targeting NY-ESO-1, conjugates and fusion proteins comprising the TCR, immune cells expressing the TCR, and T cell drugs comprising the same, as well as their use for preventing or treating tumors. Background Art
[0002] NY-ESO-1 (New York esophageal squamous cell carcinoma 1), encoded by the CTAG1B gene located on the X chromosome, belongs to the cancer-testis antigen (CTA) family. NY-ESO-1 is an ideal immunotherapy target due to its following characteristics: 1. Its expression is restricted to human testicular tissue and some cancer tissues, such as melanoma, synovial sarcoma, and multiple myeloma; 2. The human reproductive system naturally lacks human leukocyte antigen (HLA) expression, preventing antigen presentation to T cells, making NY-ESO-1-targeted cell therapy extremely low in side effects; 3. Heterologous expression of NY-ESO-1 in cancer patients is often accompanied by strong cellular and humoral immunity, indicating its high immunogenicity. These characteristics of NY-ESO-1 determine its effectiveness and safety as a target for T cell receptor therapy.
[0003] NY-ESO-1 is re-expressed in a variety of tumor cells. The most common tumor types are myxoid round cell liposarcoma, neuroblastoma, synovial sarcoma, melanoma and ovarian cancer. Other tumor types include myeloma, bladder cancer, esophageal cancer, liver cancer, head and neck cancer, non-small cell lung cancer, prostate cancer, breast cancer, etc., with NY-ESO-1 expression ranging from 20-40%.
[0004] Knuth A. et al. studied the culture of T cells (NW38-IVS-1) infiltrating melanoma tissue and discovered specific anti-NY-ESO-1 T cells. By isolating and cloning T cell receptors, they obtained the anti-NY-ESO-1 T cell receptor 1G4 and identified its recognition of the HLA-A*02:01 restricted p157-165 peptide segment ( E, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998 Jan 19; 187(2): 265-70.). Immunocore and Adaptimmune used T cell receptor affinity maturation technology to improve the affinity of 1G4 and obtained a new generation of C259 clones through in vitro screening. Currently, NY-ESO-1c259 cloned T cell receptor therapy is in the Phase II clinical stage; in its Phase I clinical trial, c259T cells can efficiently eliminate solid tumors expressing NY-ESO-1 (melanoma, synovial sarcoma, multiple myeloma), with a clinical response rate of 50% to 91% (Robbins PF, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 1; 29(7):917-24; Rapoport AP, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015 Aug; 21(8):914-921.); c259T cells are expanding their clinical indications to include ovarian cancer, renal cell carcinoma, non-small cell lung cancer, etc.
[0005] T-cell receptor engineered T cells (TCR-T) represent a novel therapeutic approach. TCR-T cells primarily rely on affinity-optimized or native TCRs to recognize antigens presented by tumor MHC molecules, delivering stimulatory signals intracellularly via the TCR-CD3 complex. Consequently, the T cell activation process they initiate more closely resembles that of natural T cells and can recognize tumor antigens presented by MHC. Based on patient T cells, they are expanded and genetically engineered in vitro. Upon activation, they can specifically lyse tumor cells, killing them. This approach offers a short treatment cycle, rapid efficacy, and the ability to afford patients sufficient time to await bone marrow transplantation, potentially leading to a complete cure.
[0006] T cell receptors are generated by VDJ gene rearrangement, and the naturally occurring T cell receptor repertoire has a capacity of approximately 10 16 According to the study (Robins HS, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009 Nov 5; 114(19): 4099-107.), the T-cell receptor library capacity is about 1000 to 10000 times that of the B-cell receptor library capacity. Such a large library capacity corresponds to the human leukocyte antigen system. HLA is divided into type I and II, which present peptides of different lengths (9-13mer). The c259 T-cell receptor recognizes the p157-165 peptide segment, which is restricted to HLA-A*02:01, 02:05, and 02:06. The distribution frequency of these three alleles in the American Caucasian population is about 48.8% (n=61655). Therefore, the c259 T-cell therapy is applicable to a wide range of Caucasian populations. HLA alleles are semi-inherited and have a strong regional genetic distribution; the top three HLA-A gene ratios in the Caucasian population are HLA-A*02:01, 01:01 and 03:01; in China, the top three HLA-A gene ratios are HLA-A*02, HLA-A*11 and HLA-A*24, among which the top three allele distributions are HLA-A*11:01, 02:01 and 24:02.
[0007] The affinity of TCR-T to the peptide presented by MHC determines whether TCR-T cells can be activated and kill tumor cells. Therefore, it is particularly important to screen for affinity maturation of TCR-T-based therapies. The necessity of affinity maturation of naturally occurring T cell receptors (e.g., tumor-specific TCRs isolated from patient peripheral blood) includes the following: 1. Naturally occurring T cell receptors have a relatively low affinity, with a KD of approximately 10 μM. For example, studies in mice immunized with LCMV strains have shown that persistent infection with the c13 strain induces very low affinity T cell receptors in vivo (Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 9; 439(7077): 682-7.). Persistent infection often leads to T cell exhaustion. 2. Early studies have shown that cancer vaccine immunization induces a strong cellular immune response and polyclonal T cell expansion in patients, and that patients who achieve clinical responses (~8%) have the highest affinity T cell receptors that exert anti-tumor activity (Coulie PG, et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev. 2002). Oct; 188: 33-42.); 3. High-affinity chimeric antigen receptor T cells can more effectively eliminate tumor tissue, so the affinity of T cell receptor or CAR is very important for maintaining T cell effector function and anti-tumor activity.
[0008] In summary, improving the affinity of TCR targeting NY-ESO-1 can improve the recognition, specific activation, cytokine secretion and killing efficiency of TCR-T cells for tumor cells. Therefore, it is necessary to develop TCR with higher NY-ESO-1 affinity.
[0009] Summary of the Invention
[0010] The inventors of this application used cell display technology to perform affinity maturation screening on the 1G4 clone. The resulting mutant clones exhibited enhanced affinity for HLA-A*0201-NY-ESO-1, improving their killing efficiency against NY-ESO-1-positive tumor cells. TCRs with enhanced affinity can be used in the development of TCR drugs, including TCR-T cell therapies and soluble TCR drugs. This provides the following invention.
[0011] T cell receptor
[0012] In one aspect, the present invention provides a T cell receptor or an antigen-binding fragment thereof targeting NY-ESO-1, wherein the TCR or antigen-binding fragment thereof comprises an α chain variable region (Vα) and / or a β chain variable region (Vβ), wherein the Vα comprises a CDRα1 as shown in SEQ ID NO: 1, a CDRα2 as shown in SEQ ID NO: 2, and a CDRα3 as shown in SEQ ID NO: 3; and the Vβ comprises a CDRβ1 as shown in SEQ ID NO: 4, a CDRβ2 as shown in SEQ ID NO: 5, and a CDRβ3 as shown in SEQ ID NO: 6.
[0013] In certain embodiments, the Vβ comprises FRβ2 as set forth in SEQ ID NO: 12. In certain embodiments, the Vβ further comprises FRβ1 as set forth in SEQ ID NO: 11, FRβ3 as set forth in SEQ ID NO: 13, and FRβ4 as set forth in SEQ ID NO: 14.
[0014] In certain embodiments, the Vβ comprises a sequence as set forth in SEQ ID NO: 16. In certain embodiments, the Vβ comprises a variant of the sequence set forth in SEQ ID NO: 16, the variant having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO: 16, and comprising CDRβ1-CDRβ3 as set forth in SEQ ID NOs: 4-6. In certain embodiments, the variant further comprises FRβ2 as set forth in SEQ ID NO: 12. In certain embodiments, the variant comprises one or more (e.g., 1, 2, 3, 4, or 5) amino acid substitutions (e.g., conservative substitutions) in FRβ1, FRβ3, and / or FRβ4 compared to SEQ ID NO: 16.
[0015] In certain embodiments, the Vα comprises FRα1 as shown in SEQ ID NO:7, FRα2 as shown in SEQ ID NO:8, FRα3 as shown in SEQ ID NO:9, and FRα4 as shown in SEQ ID NO:10.
[0016] In certain embodiments, the Vα comprises the sequence set forth in SEQ ID NO: 15. In certain embodiments, the Vα comprises a variant of the sequence set forth in SEQ ID NO: 15, the variant having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO: 15, and comprising CDRα1-CDRα3 set forth in SEQ ID NOs: 1-3. In certain embodiments, the variant comprises one or more (e.g., 1, 2, 3, 4, or 5) amino acid substitutions (e.g., conservative substitutions) in FRα1, FRα2, FRα3, and / or FRα4 compared to SEQ ID NO: 15.
[0017] In certain embodiments, the Vα comprises the sequence shown in SEQ ID NO:15, and / or the Vβ comprises the sequence shown in SEQ ID NO:16.
[0018] In certain embodiments, the TCRs of the invention can be used in any TCR configuration.
[0019] In certain embodiments, the TCR can be a full-length TCR comprising a full-length α chain and a full-length β chain. In certain embodiments, the TCR further comprises a constant region, such as a human constant region or a mouse constant region. TCR constant region sequences are well known to those skilled in the art and can be obtained through various public databases such as IMGT.
[0020] In certain embodiments, the TCR of the present invention comprises an α chain and a β chain, wherein the α chain comprises Vα and an α chain constant region (TRAC) as defined in any of the above embodiments, and the β chain comprises Vβ and a β chain constant region (TRBC1 or TRBC2) as defined in any of the above embodiments.
[0021] In certain embodiments, the TCR is a soluble TCR lacking one or more transmembrane regions and / or cytoplasmic regions. In certain embodiments, a soluble TCR is produced by fusing the extracellular domain of the TCR of the invention to other protein domains (e.g., maltose binding protein, thioredoxin, human constant kappa domain, or leucine zipper), see e.g., et al., Front Oncol., 2014;4:378, which is incorporated herein by reference in its entirety.
[0022] In certain embodiments, TCR may also be a single-chain TCR (scTCR), which includes Vα and Vβ connected by a peptide linker. Such scTCR may include Vα and Vβ, each of which is connected to a TCR constant region. Alternatively, scTCR may include Vα and Vβ, wherein Vα, Vβ, or both Vα and Vβ are not connected to a TCR constant region. Exemplary scTCRs are described in PCT Publications Nos. WO 2003 / 020763, WO 2004 / 033685, and WO 2011 / 044186, each of which is incorporated herein by reference in its entirety.
[0023] In certain embodiments, the TCR of the present invention may include two polypeptide chains (e.g., α chain and β chain), wherein the chains have been engineered to each have a cysteine residue that can form an interchain disulfide bond. Therefore, the TCR of the present invention may include two polypeptide chains connected by an engineered disulfide bond. Exemplary TCRs with engineered disulfide bonds are described in U.S. Patents Nos. 8,361,794 and 8,906,383, each of which is incorporated herein by reference in its entirety.
[0024] In certain embodiments, the TCR is a membrane-bound or soluble T cell receptor. In certain embodiments, the TCR is a full-length TCR, a soluble TCR, or a single-chain TCR.
[0025] In certain embodiments, the TCR or antigen-binding fragment thereof is capable of recognizing a NY-ESO-1 epitope peptide-MHC complex. In certain embodiments, when the TCR or antigen-binding fragment thereof is expressed on the surface of a T cell, the T cell is activated when co-cultured with a second cell displaying (e.g., displayed in the context of MHC) the NY-ESO-1 epitope peptide. In certain embodiments, T cell activation can be measured using any suitable indicator known in the art. Non-limiting examples of such suitable indicators include: increased secretion levels of cytokines (e.g., IL-2, IFN-γ, etc.), proliferation activity, and / or expression levels of activation markers (e.g., CD25, CD69, CD107a, etc.). In certain embodiments, activation of a T cell also includes the T cell inducing apoptosis or cell death of a second cell displaying (e.g., displayed in the context of MHC) the NY-ESO-1 epitope peptide.
[0026] In certain embodiments, the NY-ESO-1 epitope peptide is SLLMWITQC. In certain embodiments, the MHC molecule is HLA-A*0201.
[0027] Conjugates and fusion proteins
[0028] In another aspect, the present invention provides a conjugate comprising a TCR or antigen-binding fragment thereof as described herein and an effector moiety conjugated thereto.
[0029] In this context, the term "effector moiety" refers to a component or functional group that can modulate (e.g., increase or decrease) the natural activity of a molecule to which it is attached or confer a novel activity to the molecule. In some embodiments, the effector moiety is a biologically active compound or polypeptide (e.g., a compound or polypeptide that has an effect on cells targeted by a TCR) or a detectable marker.
[0030] In this context, the term "conjugation" refers to any method known in the art for functionally connecting protein domains, including but not limited to: recombinant fusion with or without a linker, intein-mediated fusion, non-covalent binding and covalent bonding, such as disulfide bonding, peptide bonding, hydrogen bonding, electrostatic bonding and conformational bonding, such as biotin-avidin binding. In certain embodiments, conjugation to the effector moiety can be performed by chemical or recombinant means, wherein the chemical means is to form a covalent bond between two molecules to form one molecule.
[0031] In certain embodiments, the effector moiety can be a therapeutic moiety. A therapeutic moiety refers to a compound or polypeptide that can be used as a therapeutic agent. The conjugate utilizes the targeting properties of the TCR to enable the therapeutic moiety to produce a therapeutic effect on the cells targeted by the TCR.
[0032] In certain embodiments, the TCR or antigen-binding fragment thereof of the invention is optionally conjugated to an effector moiety via a linker (e.g., a peptide linker). In certain embodiments, the effector moiety is attached to the N-terminus or C-terminus of the TCR or antigen-binding fragment thereof of the invention.
[0033] In certain embodiments, when the effector moiety is a peptide or protein, the conjugate is preferably a fusion protein.
[0034] In another aspect, the present invention also provides a fusion protein comprising the TCR or antigen-binding fragment thereof described herein and another peptide or protein.
[0035] In certain embodiments, the TCR or antigen binding fragment thereof of the present invention is optionally fused to another peptide or protein via a peptide linker. In certain embodiments, the other peptide or protein is connected to the N-terminus or C-terminus of the TCR or antigen binding fragment thereof of the present invention.
[0036] In certain embodiments, the additional peptide or protein can be selected from various molecules that are peptides or proteins as described above in the effector moiety.
[0037] Preparation of TCR and fusion proteins
[0038] The TCRs or fusion proteins comprising the TCRs of the present invention can be prepared by various methods known in the art, such as by genetic engineering and recombinant techniques. For example, DNA molecules encoding them can be obtained by chemical synthesis or PCR amplification; the resulting DNA molecules can be inserted into expression vectors, which are then transfected into host cells; the transfected host cells can then be cultured under specific conditions to express the TCRs or fusion proteins comprising the TCRs of the present invention.
[0039] On the other hand, the present invention provides an isolated nucleic acid molecule comprising: a nucleotide sequence encoding the TCR or antigen-binding fragment thereof or its α chain variable region and / or β chain variable region described herein; or a nucleotide sequence encoding the fusion protein described herein.
[0040] In certain embodiments, the isolated nucleic acid molecule comprises a first nucleotide sequence encoding an α chain variable region of a TCR or antigen-binding fragment thereof as described herein and a second nucleotide sequence encoding a β chain variable region thereof. In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are optionally connected by a nucleotide sequence encoding a self-cleaving peptide (e.g., P2A, E2A, F2A, or T2A). In certain embodiments, the self-cleaving peptide is P2A.
[0041] In certain embodiments, the isolated nucleic acid molecule comprises a first nucleotide sequence encoding the TCR alpha chain variable region and a second nucleotide sequence encoding the TCR beta chain variable region.
[0042] In certain embodiments, the isolated nucleic acid molecule comprises a first nucleotide sequence encoding the alpha chain of the TCR or antigen-binding fragment thereof and a second nucleotide sequence encoding the beta chain of the TCR or antigen-binding fragment thereof.
[0043] In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are present on different, separate nucleic acid molecules.
[0044] In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are present in any order on the same isolated nucleic acid molecule; in certain embodiments, the first nucleotide sequence and the second nucleotide sequence are connected in any order by a nucleotide sequence encoding a self-cleaving peptide (e.g., P2A).
[0045] In another aspect, the present invention provides a vector (e.g., a cloning vector or an expression vector) comprising an isolated nucleic acid molecule as described herein. In certain embodiments, the vector is, for example, a plasmid, a cosmid, a phage, or the like. In certain embodiments, the vector comprises a nucleotide sequence encoding a TCR or antigen-binding fragment thereof, or its α chain variable region and / or β chain variable region, or its α chain and / or β chain as described above.
[0046] In certain embodiments, the vector comprises a first nucleotide sequence encoding the TCR alpha chain variable region and a second nucleotide sequence encoding the TCR beta chain variable region.
[0047] In certain embodiments, the vector comprises a first nucleotide sequence encoding the α chain of the TCR or antigen-binding fragment thereof and a second nucleotide sequence encoding the β chain of the TCR or antigen-binding fragment thereof.
[0048] In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are present on different vectors.
[0049] In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are present in any order on the same vector.In certain embodiments, the first nucleotide sequence and the second nucleotide sequence are connected in any order by a nucleotide sequence encoding a self-cleaving peptide (e.g., P2A).
[0050] In certain embodiments, the vector comprises a nucleotide sequence encoding a fusion protein as described above.
[0051] In certain embodiments, the vector is a viral vector, such as a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector, or a baculoviral vector.
[0052] In another aspect, the present invention provides a host cell comprising an isolated nucleic acid molecule or vector as described herein. Such host cells include, but are not limited to, prokaryotic cells such as Escherichia coli cells, and eukaryotic cells such as yeast cells, insect cells, plant cells, and animal cells (e.g., mammalian cells, such as mouse cells, human cells, etc.).
[0053] On the other hand, a method for preparing the TCR or a fusion protein comprising TCR described herein is also provided, which comprises culturing the host cell described above under conditions allowing protein expression, and recovering the TCR or a fusion protein comprising TCR from the cultured host cell culture.
[0054] Engineered immune cells
[0055] The TCRs or antigen-binding fragments thereof described herein can be used in T cell-based immunotherapy. In some cases, T cells expressing the TCRs described herein recognize MHC-peptide complexes to achieve killing of tumor cells.
[0056] In another aspect, the present invention provides an engineered immune cell that expresses the TCR or antigen-binding fragment thereof described herein on the cell surface.
[0057] The engineered immune cells of the present invention are capable of recognizing NY-ESO-1 epitope peptide-MHC complexes. In certain embodiments, the engineered immune cells are activated when co-cultured with a second cell displaying the NY-ESO-1 epitope peptide (e.g., displayed in the context of MHC). Non-limiting examples of such activation include: increased secretion of cytokines (e.g., IL-2, IFN-γ, etc.), proliferation activity, and / or expression of activation markers (e.g., CD25, CD69, CD107a, etc.). In certain embodiments, the engineered immune cells induce apoptosis or cell death in the second cell displaying the NY-ESO-1 epitope peptide (e.g., displayed in the context of MHC).
[0058] In certain embodiments, the NY-ESO-1 epitope peptide is SLLMWITQC. In certain embodiments, the MHC molecule is HLA-A*0201.
[0059] In certain embodiments, the engineered immune cell comprises a nucleotide sequence encoding a TCR or antigen-binding fragment thereof described herein.
[0060] Immune cells as described herein can be separated or obtained from any tissue in which such cells are found. For example, they can be found in peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, ascites, pleural effusion, spleen tissue or tumors of mammals, and then optionally cultured and sorted in a culture medium containing appropriate cytokines to obtain the desired immune cells. Alternatively, the immune cells can also be cultured and provided in other ways, such as from precursor cells of immune cells (e.g., precursors of T lymphocytes) through induced differentiation, the precursor cells can be, for example, pluripotent stem cells (e.g., embryonic stem cells, induced pluripotent stem cells), hematopoietic stem cells or lymphocyte progenitor cells, which are separated and / or enriched from, for example, bone marrow, cord blood or peripheral blood.
[0061] In certain embodiments, the immune cell is a lymphocyte. In certain embodiments, the immune cell is selected from T cells, tumor infiltrating lymphocytes (TIL), natural killer (NK) cells, natural killer T (NKT) cells or any combination thereof. Exemplary immune cells that can be used to express the TCR of the present invention include PBMC, TIL and / or T cells. In certain embodiments, T cells are selected from: αβT cells, γδT cells, iPSC-induced T cells, CD8+ cytotoxic T cells, CD4+ cytotoxic T cells, CD4+ helper T cells (for example, Th1 or Th2 cells), CD4 / CD8 double positive T cells, tumor infiltrating T cells, thymocytes, memory T cells, natural killer T cells, for example, constant natural killer T cells. It will be understood by those skilled in the art that immune cells can also include progenitor cells (precursor cells) of immune cells, wherein the progenitor cells can be induced in vivo or in vitro to differentiate into immune cells. Thus, in certain embodiments, the immune cells include immune cell progenitors, such as hematopoietic stem cells (HSCs) contained within a CD34+ cell population derived from cord blood, bone marrow, or circulating peripheral blood, which differentiate into mature immune cells after administration to a subject, or which can be induced in vitro to differentiate into mature immune cells.
[0062] In certain embodiments, the engineered immune cell is a T cell receptor engineered T cell (TCR-T).
[0063] The immune cells described herein can be self / autologous ("self") or non-self ("non-self," e.g., allogeneic). "Self" refers to cells from the same subject; "allogeneic" refers to cells of the same species that are genetically different from the comparison cells.
[0064] In certain embodiments, the immune cells are isolated from an HLA-A*0201 positive subject.
[0065] It should be understood that the engineered immune cells of the present invention can be contained in a separate cell population. The cell population can be a heterogeneous population, for example, the cell population contains at least one other cell in addition to the engineered immune cells of the present invention, the other cell not having antigenic specificity for NY-ESO-1, or, for example, the cell population contains more than one type of immune cell, but all of these types of immune cells express the TCR of the present invention and thus have antigenic specificity for NY-ESO-1. In addition, the cell population can also be a substantially homogeneous population, for example, wherein the population primarily comprises (e.g., consists essentially of) T cells having antigenic specificity for NY-ESO-1.
[0066] On the other hand, the present invention provides a method for preparing the above-mentioned modified immune cells, which comprises: (1) providing immune cells from a subject; (2) introducing a nucleic acid molecule or vector comprising a nucleotide sequence encoding the TCR or its antigen-binding fragment of the present invention into the immune cells described in step (1) to obtain immune cells expressing the TCR or its antigen-binding fragment.
[0067] In certain embodiments, in step (1), the immune cells are pretreated; the pretreatment includes sorting, activating and / or proliferating the immune cells. In certain embodiments, the pretreatment includes contacting the immune cells with one or more selected from anti-CD3 antibodies, anti-CD28 antibodies, IL-2 and IL-15, thereby stimulating the immune cells and inducing their proliferation, thereby generating pretreated immune cells.
[0068] In certain embodiments, in step (2), the nucleic acid molecule or vector can be introduced into the immune cells by various suitable means, such as calcium phosphate transfection, DEAE-dextran-mediated transfection, microinjection, electroporation, TALEN method, ZFN method, non-viral vector-mediated transfection (such as liposome) or viral vector-mediated transfection (such as lentiviral infection, retroviral infection, adenoviral infection), and other physical, chemical or biological means for transfer into host cells, such as transposon technology, CRISPR-Cas9 and other technologies.
[0069] In certain embodiments, after step (2), the method further comprises: expanding the immune cells obtained in step (2).
[0070] Therapeutic applications
[0071] The TCR of the present invention or the immune cell expressing the TCR can be used in T cell-based immunotherapy to kill tumors.
[0072] On the other hand, the present invention provides a pharmaceutical composition comprising: a TCR or antigen-binding fragment thereof, conjugate, or fusion protein described herein, or an isolated nucleic acid molecule, vector, or host cell described herein, or a modified immune cell described herein; and a pharmaceutically acceptable carrier and / or excipient.
[0073] In certain embodiments, the pharmaceutical composition further comprises an additional therapeutic agent, such as an anti-tumor agent or an immune-enhancing agent.
[0074] In certain embodiments, the anti-tumor agent is selected from alkylating agents, mitotic inhibitors, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radionuclide agents, radiosensitizers (e.g., gemcitabine, 5-fluorouracil, taxanes, cisplatin, etc.), anti-angiogenic agents, cytokines (e.g., GM-CSF, IL-7, IL-12, IL-15, IL-18, IL-21, etc.), antibodies specifically targeting tumor cells (e.g., CD20 antibodies such as rituximab, Her2 antibodies such as trastuzumab, VEGF antibodies such as bevacizumab, EGFR antibodies such as cetuximab, etc.), immune checkpoint inhibitors (e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody or TIM3 antibody).
[0075] In certain embodiments, the immune enhancer is selected from an immunostimulatory antibody (e.g., an anti-CD3 antibody, an anti-CD28 antibody, an anti-CD40L (CD154) antibody, an anti-41BB (CD137) antibody, an anti-OX40 antibody, an anti-GITR antibody, or any combination thereof) or an immunostimulatory cytokine (e.g., IL-2, IL-3, IL-12, IL-15, IL-18, IFN-γ, IL-10, TGF-β, GM-CSF, or any combination thereof).
[0076] In certain embodiments, in the pharmaceutical composition, the TCR or antigen-binding fragment thereof, conjugate, fusion protein or engineered immune cell of the present invention and the additional therapeutic agent can be provided as separate components or as mixed components.
[0077] On the other hand, the present invention provides a method for preventing or treating a tumor in a subject, comprising administering to a subject in need thereof an effective amount of a TCR or its antigen-binding fragment, conjugate, or fusion protein as described herein, or an isolated nucleic acid molecule, vector, or host cell as described herein, or a modified immune cell as described herein, or a pharmaceutical composition as described herein. Also provided is a TCR or its antigen-binding fragment, conjugate, or fusion protein as described herein, or an isolated nucleic acid molecule, vector, or host cell as described herein, or a modified immune cell as described herein, or a pharmaceutical composition as described herein, for use in the preparation of a medicament for preventing or treating a tumor in a subject.
[0078] In certain embodiments, the tumor is a NY-ESO-1 positive tumor. In this context, NY-ESO-1 positivity can be determined by classical immunological methods, such as immunohistochemistry and staining intensity evaluation.
[0079] In certain embodiments, the tumor is a solid tumor. In certain embodiments, the tumor is selected from myxoid liposarcoma (such as myxoid round cell liposarcoma), synovial sarcoma (such as neuroblastoma synovial sarcoma), melanoma, multiple myeloma, ovarian cancer, renal cell carcinoma, non-small cell lung cancer, bladder cancer, esophageal cancer, liver cancer, head and neck cancer, prostate cancer, breast cancer.
[0080] In certain embodiments, the subject is a human.
[0081] In certain embodiments, the subject is HLA-A*0201-positive. Herein, HLA-A*0201 positivity can be determined by any HLA typing method known in the art, such as PCR-sequence specific primers (SSP), PCR-sequence-specific oligonucleotide (SSO), real-time PCR, sequencing-based typing (SBT), next-generation sequencing (NGS), and the like.
[0082] In certain embodiments, the method comprises: (1) providing a subject with immune cells required by the subject; (2) introducing a nucleotide sequence encoding the TCR or its antigen-binding fragment of the present invention into the immune cells described in step (1) to obtain immune cells expressing the TCR or its antigen-binding fragment on the surface; and (3) administering the immune cells obtained in step (2) to the subject.
[0083] In certain embodiments, the step of obtaining immune cells from the subject is included before step (1). Immune cells can be isolated or obtained from any tissue in which such cells are found (e.g., peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, ascites, pleural effusion, spleen tissue, and tumor), or can be cultured and provided in other ways, such as from immune cell precursor cells (e.g., precursors of T lymphocytes) through induced differentiation.
[0084] In certain embodiments, the immune cell is selected from lymphocytes. In certain embodiments, the immune cell is selected from T cells (e.g., αβT cells, γδT cells, or iPSC-induced T cells), tumor infiltrating lymphocytes (TILs), natural killer (NK) cells, natural killer T (NKT) cells, or any combination thereof.
[0085] In certain exemplary embodiments, peripheral blood mononuclear cells (PBMCs) and / or TILs are obtained from the subject and genetically modified directly to express a TCR.
[0086] In certain exemplary embodiments, T cells are obtained from the subject and genetically modified to express a TCR. T cells can be obtained from a variety of sources, for example, using a variety of techniques known to those skilled in the art (e.g., deposition, e.g., Ficoll). TM In one embodiment, T cells are obtained from a blood unit collected from an object by plasmapheresis (separation). In one embodiment, cells from individual circulating blood are obtained by plasmapheresis (apheresis). The product of plasmapheresis usually contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, red blood cells and platelets. In one embodiment, the cells collected by plasmapheresis can be washed to remove the plasma fraction, and the cells are placed in a suitable buffer or medium for subsequent processing. As will be appreciated by those skilled in the art, washing steps can be completed by methods known to those skilled in the art, such as by using a semi-automatic flow-through centrifuge. After washing, cells can be resuspended in a variety of biocompatible buffers or other saline solutions containing or not containing buffers. In certain embodiments, unwanted components can be removed in the culture medium in which cells are directly resuspended. In certain embodiments, by lysing red blood cells and exhausting mononuclear cells (e.g., by centrifuging with a Percoll TM Gradient centrifugation) is used to separate T cells from peripheral blood mononuclear cells (PBMC). Specific T cell subpopulations expressing one or more of the following markers can be further isolated by positive or negative selection techniques: CD3, CD28, CD4, CD8, CD45RA, and CD45RO. In one embodiment, specific T cell subpopulations expressing CD3, CD28, CD4, CD8, CD45RA, and CD45RO are further isolated by positive or negative selection techniques. For example, the enrichment of T cell populations by negative selection can be accomplished using a combination of antibodies against surface markers specific to negatively selected cells. An exemplary method is cell sorting and / or selection by negative magnetic immunoadhesion or flow cytometry, which utilizes a mixture of monoclonal antibodies against cell surface markers present on negatively selected cells. Flow cytometry and cell sorting can also be used to separate the target cell populations used in the present invention.
[0087] In certain embodiments, immune cells (such as T cells) can be activated and expanded (or, in the case of progenitor cells, differentiated) in vitro prior to genetic modification.
[0088] In certain embodiments, TCR or its antigen binding fragment, conjugate or fusion protein as described herein, or isolated nucleic acid molecule, vector or host cell as described herein, or modified immune cell as described herein, or pharmaceutical composition as described herein can be co-administered with another therapeutic agent (e.g., immunopotentiator or anti-tumor agent). Therefore, in certain embodiments, the method further comprises administering another therapeutic agent (e.g., immunopotentiator or anti-tumor agent) to the subject, e.g., simultaneously, separately or sequentially.
[0089] In certain embodiments, the TCRs described herein, or antigen-binding fragments thereof, conjugates, or fusion proteins, or isolated nucleic acid molecules, vectors, or host cells described herein, or modified immune cells described herein, or pharmaceutical compositions described herein, can be administered in combination with additional therapies, e.g., simultaneously, separately, or sequentially. Such additional therapies can be any therapy known for tumors, e.g., surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, hormone therapy, gene therapy, or palliative care.
[0090] The TCR or its antigen-binding fragment, conjugate, fusion protein, isolated nucleic acid molecule, vector, host cell, modified immune cell, or pharmaceutical composition comprising the same of the present invention can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injection and concentrated solutions for injection), inhalants, sprays, etc. The preferred dosage form depends on the intended mode of administration and therapeutic use. The drug of the present invention should be sterile and stable under production and storage conditions. A preferred dosage form is an injection. Such an injection can be a sterile injection solution. For example, a sterile injectable solution can be prepared by the following method: incorporating the necessary dose of the TCR or its antigen-binding fragment, conjugate, fusion protein, modified immune cell of the present invention, or a pharmaceutical composition comprising the same in an appropriate solvent, and optionally, simultaneously incorporating other desired ingredients (including but not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by filtration sterilization. In addition, the sterile injectable solution can be prepared as a sterile lyophilized powder (e.g., by vacuum drying or freeze drying) for easy storage and use. Such sterile lyophilized powders can be dispersed in a suitable carrier before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffer solution (e.g., phosphate buffer solution), Ringer's solution, and any combination thereof.
[0091] Thus, in certain exemplary embodiments, the pharmaceutical compositions described herein comprise a sterile injectable liquid (e.g., an aqueous or non-aqueous suspension or solution). In certain exemplary embodiments, such sterile injectable liquid is selected from water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), a solution containing a surfactant (e.g., 0.01% polysorbate 20), a pH buffered solution (e.g., phosphate buffered solution), Ringer's solution, and any combination thereof.
[0092] The TCR of the present invention or its antigen-binding fragment, conjugate, fusion protein, isolated nucleic acid molecule, vector, host cell, transformed immune cell or pharmaceutical composition comprising them can be applied by any suitable method known in the art, including but not limited to, oral, oral, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (such as, powder, ointment or drops), or nasal route. However, for many therapeutic uses, the preferred route of administration / mode is parenteral administration (such as intravenous injection or push injection, subcutaneous injection, intraperitoneal injection, intramuscular injection). Technicians will understand that the route of administration and / or mode will change according to the intended purpose. In certain embodiments, the TCR of the present invention or its antigen-binding fragment, conjugate, fusion protein, isolated nucleic acid molecule, vector, host cell, transformed immune cell or pharmaceutical composition comprising them is administered by intravenous injection or push injection.
[0093] The pharmaceutical compositions described herein may include an "effective amount" of a TCR or antigen-binding fragment thereof, conjugate, fusion protein, isolated nucleic acid molecule, vector, host cell, modified immune cell, or pharmaceutical composition comprising the same. The term "effective amount" refers to an amount sufficient to achieve or at least partially achieve a desired effect. For example, a "therapeutically effective amount" is an amount capable of producing an anti-tumor effect in a treated subject, including reducing or inhibiting the proliferation of tumor cells and / or eliminating tumor cells.
[0094] Definition of terms
[0095] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, procedures in immunology, molecular biology, biochemistry, nucleic acid chemistry, cell culture, and the like used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0096] As used herein, the term "NY-ESO-1 (New York esophageal squamous cell carcinoma 1)" refers to a protein encoded by the CTAG1B gene located on chromosome X. The sequence of NY-ESO-1 is well known to those skilled in the art and can be found in various public databases, such as NCBI: gene ID 1485.
[0097] As used herein, the terms "major histocompatibility complex" and "MHC" are used interchangeably. They are a group of genes that determine whether transplanted tissues are identical, are closely related to immune responses, and are tightly linked. They primarily include MHC-I and MHC-II molecules. "MHC-I" refers to a dimer of the MHC class I α chain and the β2 microglobulin chain, while "MHC-II" refers to a dimer of the MHC class II α chain and the MHC class II β chain. The human MHC is called the human leukocyte antigen (HLA) complex.
[0098] As used herein, the term "MHC-epitope peptide complex" refers to an MHC molecule (MHC class I or MHC class II) comprising a peptide bound to an art-recognized MHC peptide binding pocket. In some cases, the MHC molecule may be a membrane-bound protein expressed on the cell surface. In other cases, the MHC molecule may be a soluble protein lacking a transmembrane region or a cytoplasmic region.
[0099] As used herein, the terms "T cell receptor" and "TCR" are used interchangeably and refer to molecules comprising CDRs or variable regions from αβ or γδ T cell receptors. Examples of TCRs include, but are not limited to, full-length TCRs, antigen-binding fragments of TCRs, soluble TCRs lacking transmembrane and cytoplasmic regions, single-chain TCRs containing TCR variable regions attached by flexible linkers, TCR chains linked by engineered disulfide bonds, and the like.
[0100] As used herein, the term "full-length TCR" refers to a TCR comprising a dimer of a first polypeptide chain and a second polypeptide chain, each of which comprises a TCR variable region and a TCR constant region comprising a TCR transmembrane region and a TCR cytoplasmic region. In certain embodiments, a full-length TCR comprises a mature full-length TCR α chain and a mature full-length TCR β chain. In certain embodiments, a full-length TCR comprises a mature full-length TCR γ chain and a mature full-length TCR δ chain.
[0101] As used herein, the term "TCR variable region" refers to the portion of a mature TCR polypeptide chain (e.g., a TCR alpha chain or beta chain) that is not encoded by the TRAC gene of the TCR alpha chain, the TRBC1 gene or the TRBC2 gene of the TCR beta chain, the TRDC gene of the TCR delta chain, or the TRGC1 gene or the TRGC2 gene of the TCR gamma chain. In certain embodiments, the TCR variable region of the TCR alpha chain encompasses all the amino acids of a mature TCR alpha chain polypeptide encoded by the TRAV gene and / or the TRAJ gene, and the TCR variable region of the TCR beta chain encompasses all the amino acids of a mature TCR beta chain polypeptide encoded by the TRBV gene, the TRBD gene, and / or the TRBJ gene (see, e.g., T cell receptor Factsbook, (2001), LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8, which is incorporated herein by reference in its entirety). The TCR variable region generally includes framework regions (FR) 1, 2, 3 and 4 and complementarity determining regions (CDR) 1, 2 and 3. Herein, the terms "α chain variable region" and "Vα" are used interchangeably and refer to the variable region of the TCR α chain. The terms "β chain variable region" and "Vβ" are used interchangeably and refer to the variable region of the TCR β chain.
[0102] As used herein, the term "CDR" or "complementarity determining region" with respect to TCR refers to the non-contiguous antigen binding sites found within the variable region of a TCR chain (e.g., an α chain or a β chain). These regions have been described in Lefranc, (1999) The Immunologist 7: 132-136; Lefranc et al., (1999) Nucleic Acids Res 27: 209-212; LeFranc (2001) T Cell Receptor Databook, Academic Press, ISBN 0-12-441352-8; Lefranc et al., (2003) Dev Comp Immunol 27 (1): 55-77; and in Kabat et al., (1991) Sequences of protein of immunological interest, each of which is incorporated herein by reference in its entirety. In certain embodiments, the CDRs are defined according to the IMGT numbering system described in Lefranc (1999), supra.
[0103] As used herein, the term "FR" or "framework region" with respect to a TCR refers to those amino acid residues in the variable region of a TCR chain (eg, α chain or β chain) other than the CDRs as defined above.
[0104] As used herein, the term "constant region" for TCR refers to a portion of a TCR encoded by the TRAC gene (for TCR alpha chains), TRBC1 or TRBC2 genes (for TCR beta chains), TRDC genes (for TCR delta chains) or TRGC1 or TRGC2 genes (for TCR gamma chains), optionally lacking all or part of a transmembrane region and / or all or part of a cytoplasmic region. In certain embodiments, the TCR constant region lacks a transmembrane region and a cytoplasmic region. The TCR constant region does not include amino acids encoded by TRAV, TRAJ, TRBV, TRBD, TRBJ, TRDV, TRDD, TRDJ, TRGV or TRGJ genes (see, e.g., T Cell Receptor Databook, (2001), LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8, which is incorporated herein by reference in its entirety).
[0105] In the context of TCRs, the term "extracellular" refers to the portion(s) of the TCR chain that are located outside the cell, "transmembrane" refers to the portion(s) of the TCR chain that are embedded in the plasma membrane of a cell, and "cytoplasmic" refers to the portion(s) of the TCR chain that are located in the cytoplasm of a cell.
[0106] As used herein, the term "antigen-binding portion" with respect to a TCR refers to any part or fragment of a TCR that retains the biological activity of the TCR (the parent TCR) as part of the TCR. The biological activity may include the ability to specifically bind to the same antigen (e.g., NY-ESO-1) or MHC-antigen complex that the parent TCR binds.
[0107] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. The strength or affinity of a specific binding interaction can be measured by the equilibrium dissociation constant (K) of the interaction. D ) indicates. In the present invention, the term "K D" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. The specific binding properties between two molecules can be measured using methods well known in the art. One method involves measuring the rate of formation and dissociation of the antigen binding site / antigen complex. Both the "association rate constant" (ka or kon) and the "dissociation rate constant" (kdis or koff) can be calculated from the concentration and the actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361: 186-187). The ratio of kdis / kon is equal to the dissociation constant K D (See Davies et al., Annual Rev Biochem, 1990; 59: 439-473). K can be measured by any effective method. D , kon and kdis values are measured, for example, by surface plasmon resonance (SPR) in Biacore, or using bioluminescence interferometry or Kinexa.
[0108] In the context of a TCR, the term "specific binding" or "specific recognition" refers to the ability of a TCR to preferentially bind to a specific antigen (e.g., a specific peptide or a specific peptide-MHC complex combination). Typically, a TCR that specifically binds to an antigen does not bind to, or binds to, other antigens with lower affinity. For example, an antigen-specific TCR binds to the target antigen with a Ka that is at least 2, 5, 10, 50, 100, 500, 1,000, 5,000, or 10,000 times greater than the association constant (Ka) of the antigen-specific TCR relative to the nonspecific antigen. In certain embodiments, the TCRs or antigen-binding fragments thereof disclosed herein specifically bind to NY-ESO-1. In certain embodiments, the TCRs or antigen-binding fragments thereof disclosed herein specifically bind to a NY-ESO-1 epitope peptide (e.g., SLLMWITQC)-HLA-A*0201 complex.
[0109] As used herein, the term "immune cell" refers to any cell of the immune system with one or more effector functions. Immune cells are typically included in cells that play a role in immune responses, and they generally have hematopoietic origins. The term "effector function" refers to the specialized functions of immune cells, such as enhancing or promoting the function or reaction of the immune attack on target cells (such as killing of target cells, or inhibiting their growth or proliferation). For example, the effector function of T cells, for example, can be cytolytic activity or auxiliary or the activity including the secretion of cytokines. The example of immune cells includes T cells (such as α / β T cells and γ / δ T cells), B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells and bone marrow-derived macrophages, etc.
[0110] The immune cells of the present invention can be self / autologous ("self") or non-self ("non-self", e.g., allogeneic, isogenic, or allogeneic). As used herein, "self" refers to cells from the same subject; "allogeneic" refers to cells of the same species that are genetically different from the comparison cells; "isogenic" refers to cells from a different subject that are genetically identical to the comparison cells; and "allogeneic" refers to cells from a different species than the comparison cells. In certain embodiments, the immune cells of the present invention are autologous or allogeneic.
[0111] As used herein, the term "cytotoxic agent" includes any agent that is detrimental to (eg, kills) cells, such as a chemotherapeutic drug, a bacterial toxin, a plant toxin, or a radioactive isotope.
[0112] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.
[0113] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells, immune cells (such as T lymphocytes, NK cells, monocytes, macrophages or dendritic cells, etc.). Host cells can include single cells or cell populations.
[0114] As used herein, the term "identity" refers to the match between two polypeptides or between two nucleic acids. When a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of the two DNA molecules is occupied by adenine, or a position in each of the two polypeptides is occupied by lysine), then the molecules are identical at that position. The "percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared x 100. For example, if 6 out of 10 positions in two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT share 50% identity (3 out of 6 positions match). Typically, two sequences are compared when they are aligned for maximum identity. Such an alignment can be achieved, for example, by using the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453, which can be conveniently performed using a computer program such as the Align program (DNAstar, Inc.). The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl Biosci., 4:11-17 (1988)), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J Mol Biol. 48:444-453 (1970)) algorithm, which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using a Blossum 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0115] The twenty conventional amino acids referred to herein are written in accordance with conventional usage. See, for example, Immunology—A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In the present invention, the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Also, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0116] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, agents that maintain osmotic pressure, agents that delay absorption, and preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like. Agents that maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like. Agents that delay absorption include, but are not limited to, monostearate and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols and polyols (such as glycerol), etc. Stabilizers have the meanings generally understood by those skilled in the art, and are capable of stabilizing the desired activity of the active ingredient in the drug, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation products (such as lactalbumin hydrolysate), etc.
[0117] As used herein, the term "prevention" refers to a method implemented in order to prevent or delay the occurrence of a disease or illness or symptom (e.g., a tumor) in a subject. As used herein, the term "treatment" refers to a method implemented in order to obtain a beneficial or desired clinical outcome. For purposes of the present invention, beneficial or desired clinical outcomes include, but are not limited to, alleviating symptoms, reducing the scope of the disease, stabilizing (i.e., no longer worsening) the state of the disease, delaying or slowing the development of the disease, improving or alleviating the state of the disease, and alleviating symptoms (whether partially or entirely), whether detectable or undetectable. In addition, "treatment" can also refer to, compared to the expected survival (if not receiving treatment), extending the survival period.
[0118] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is well within the capabilities of those skilled in the art. For example, an amount effective for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.
[0119] As used herein, the term "subject" refers to a mammal, such as a primate, such as a human. In certain embodiments, the term "subject" refers to a living organism in which an immune response can be elicited. In certain embodiments, the subject (e.g., a human) has a tumor (e.g., a NY-ESO-1 positive tumor), or is at risk for having the above-mentioned disease.
[0120] Advantageous Effects of the Invention
[0121] The present invention provides a high-affinity TCR targeting NY-ESO-1. Compared with the known NY-ESO-1 TCR, it has higher affinity and stronger tumor cell killing ability. It has significant anti-tumor activity in efficacy studies on solid tumor models. Therefore, it can be used to develop TCR drugs, including TCR-T cell therapy drugs and soluble TCR drugs, and has important clinical value.
[0122] The embodiments of the present invention will be described in detail below with reference to the accompanying drawings and examples, but it will be understood by those skilled in the art that the following drawings and examples are only intended to illustrate the present invention and are not intended to limit the scope of the invention. Based on the following detailed description of the drawings and preferred embodiments, the various objects and advantages of the present invention will become apparent to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0123] Figure 1 shows the in vitro killing results of U266-Luc tumor cells (HLA-A*02:01 and NY-ESO-1 positive) by control T cells (MockT), T cells expressing 1G4α95LY TCR, or T cells expressing 1G4C9-50ATY TCR in Example 3.
[0124] Figure 2 shows the in vitro killing results of the control T cells (MockT), T cells expressing 1G4α95LY TCR or 1G4C9-50ATY TCR in Example 3 against the T2 cell line (T2-ESO1) that is HLA-A*02:01 positive and expresses the NY-ESO-1 minigene.
[0125] FIG3 shows the in vivo anti-tumor results of control T cells (MockT), T cells expressing 1G4α95LY TCR, or T cells expressing 1G4C9-50ATY TCR in Example 4 in a mouse model.
[0126] Sequence information
[0127] Information on the partial sequences involved in the present invention is provided in the table below. Example
[0128] The present invention will now be described with reference to the following examples. Those skilled in the art will appreciate that the examples are provided for illustrative purposes only and are not intended to limit the scope of the invention. The experimental methods in the examples are conventional methods unless otherwise specified. In the examples, where specific conditions are not specified, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. Reagents or instruments used, for which the manufacturer is not specified, are all commercially available conventional products.
[0129] Example 1. Construction of 1G4 TCR mutation library
[0130] Using the 1G4 TCR as a template (the 1G4 TCR α and β chain sequences are from US Pat. No. 8088379B2, with amino acid sequences shown in SEQ ID NOs: 17 and 18, respectively, CDRα1-CDRα3 as shown in SEQ ID NOs: 1-3, and CDRβ1-CDRβ3 as shown in SEQ ID NOs: 4, 19, and 6, respectively), structural modeling was performed using pyMOL and Swiss Modeling to identify amino acid residues requiring mutation in the CDR or Framework regions. An NNK mutation library (N = A / C / G / T, K = G / T) was constructed. The 1G4 TCR mutation library was cloned into the TCR expression vector GV401 (lentiviral shuttle plasmid, GeneChip) via 5'XbaI and 3'NheI. The nucleotide sequence of the 1G4 TCR expression vector (GV401) is shown in SEQ ID NO: 22 in the sequence information table above, where the 1G4 TCR nucleotides are underlined. The recombinant expression vector was transformed into E. coli to amplify the mutation library plasmid. The obtained libraries of CDR1, CDR2, and CDR3 mutation libraries of 1G4 TCR Vα chain and Vβ chain and the αβ chain interface mutation library were named CDRα1, CDRα2, CDRα3, CDRβ1, CDRβ2, CDRβ3, and Vβ-FR2, respectively.
[0131] Table 1. 1G4 TCR CDR sequences and mutation sites
[0132] Example 2. Cell library construction and screening
[0133] The plasmid library constructed in Example 1 was co-transfected with lentiviral packaging plasmids (pRRE, pREV, pMD2.G, GeneChip) into 293T cells (purchased from ATCC, number CRL-3216). The lentiviral vector library containing TCR mutants was collected after transfection and stored at -80°C. The lentiviral vector library was transduced into the Jurkat-NFAT-EGFP cell line (constructing Jurkat cells stably expressing the NFAT Respone Element + miniPromoter-driven EGFP gene, wherein the NFAT RE + miniP sequence is shown in SEQ ID NO: 24) at an MOI of 0.3 to generate a library of 1G4 TCR mutants displayed by Jurkat cells. The 1G4 TCR mutant Jurkat cell library was mixed with antigen-presenting cells T2-ESO1 (T2 cell line overexpressing the NY-ESO-1 antigen minigene (p157-165, SEQ ID NO: 23); T2 cells were purchased from ATCC, number CRL-1992) at a cell ratio of 8:1 and cultured for 16-24 hours. The cells were collected and resuspended in FACS buffer (DPBS solution containing 1% BSA) and stained with A02-ESO1 Tetramer (MBL). The Tetramer and EGFP double-positive cell population was sorted, and the sorted cells were expanded and cultured, and the above screening process was repeated twice. After three sorting and culture, 1×10 7 Genomic DNA was extracted from each cell, and the mutant regions were amplified using primers at both ends of the HIV1 LTR and TCR mutation regions, followed by NGS library construction and sequencing. Based on the NGS sequencing results, the mutation frequency of each site was statistically analyzed, and mutants with higher mutation frequencies were selected for cell function verification. The CDRβ2 mutant 50ATY and the Vβ-FR2 mutant C9 were combined to form the mutant C9-50ATY for cell function assay. This clone was named C9-50ATY, and its Vα and Vβ sequences are shown in SEQ ID NOs:15 and 16, respectively, its CDRα1-CDRα3 are shown in SEQ ID NOs:1-3, respectively, and its CDRβ1-CDRβ3 are shown in SEQ ID NOs:4-6, respectively.
[0134] Example 3. In vitro functional assay of TCRT cells
[0135] Steven Rosenberg et al. screened for mutations in the 1G4 TCR CDRα3 and identified a high-affinity mutant, designated α95LY or 1G4 c259 clone (Robbins PF et al. J Immunol. 2008 May 1;180(9):6116-31). Compared to the 1G4 wild-type TCR, its affinity was increased 12-fold. The sequence of the α95LY clone is aligned with the 1G4 wild-type or C9-50ATY clone as follows (mutations are underlined):
[0136] Table 2: Sequence alignment
[0137] The cloned α chain variable region sequence was ligated to the murine TCRα constant region sequence, and the β chain variable region sequence was ligated to the murine TCRβ constant region sequence to form the α95LY TCR and C9-50ATY TCR, respectively. The lentiviral vectors were packaged in 293T cells using a four-plasmid lentiviral packaging system according to methods well known in the art. The lentiviral vectors were then used to transduce human T cells activated with CD3 / 28 antibodies to generate the corresponding TCR-T cells. Control T cells (MockT), human T cells expressing the 1G4α95LY TCR, or human T cells expressing the 1G4C9-50ATY TCR were co-cultured with U266-Luc tumor cells (HLA-A*02:01 and NY-ESO-1 positive; U266 cells purchased from ATCC, catalog number TIB-196) at E:T ratios of 4, 2, 1, 0.5, 0.25, and 0.125) for 16-24 hours. The tumor-killing effect of TCRT cells was measured using the ONE-Glo Luciferase Assay reagent (Promega). As shown in Figure 1, C9-50ATY TCRT cells were significantly more cytotoxic to U266-Luc tumor cells than α95LY.
[0138] In addition, the LDH assay (CytoTox Non-radioactive cytotoxicity Assay, Promega) was used to determine the cytotoxicity of MockT cells and the two 1G4 TCRT cells against the HLA-A*02:01-positive T2 cell line (T2-ESO1, same as in Example 2) expressing the NY-ESO-1 minigene (E:T ratios of 10, 3, 1, and 0.3). As shown in Figure 2, C9-50ATY TCRT was significantly more cytotoxic than α95LY against T2 cells expressing NY-ESO-1.
[0139] The above results showed that the C9-50ATY clone had stronger tumor cell killing ability than α95LY.
[0140] Example 4. In vivo efficacy study of TCRT cells
[0141] 4-6 week old B-NDG mice (NOD-SCID IL2Rγ-null, Biocytogen) were subcutaneously injected with PC9-ESO1-A0201 (PC9 tumor cells overexpressing full-length NY-ESO-1 and HLA-A*02:01; PC9 cells purchased from ATCC, No. 32727) at an inoculum of 1E7 / 100 μl / mouse. Eleven days after cell inoculation, tumors grew to 50-100 mm. 3 Tumor-bearing mice were randomly divided into four groups (n=6) and administered via the tail vein with four formulations (formulation control, MockT control, C9-50ATY TCRT, and α95LY TCRT). Tumor size was measured 2-3 times per week after administration. As shown in Figure 3, C9-50ATY TCRT significantly inhibited tumor growth in mice, demonstrating a stronger tumor inhibitory effect than α95LY TCRT.
[0142] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that various modifications and changes can be made to the details based on all the teachings published, and these changes are all within the scope of protection of the present invention. The entire invention is given by the appended claims and any equivalents thereof.
Claims
1. A T cell receptor (TCR) or an antigen binding fragment thereof targeting NY-ESO-1, comprising an α chain variable region (Vα) and / or a β chain variable region (Vβ), wherein: The Vα includes CDRα1 as shown in SEQ ID NO:1, CDRα2 as shown in SEQ ID NO:2 and CDRα3 as shown in SEQ ID NO:3; the Vβ includes CDRβ1 as shown in SEQ ID NO:4, CDRβ2 as shown in SEQ ID NO:5 and CDRβ3 as shown in SEQ ID NO:
6.
2. The TCR or antigen-binding fragment thereof according to claim 1, wherein The Vβ includes FRβ2 as shown in SEQ ID NO:12; preferably, the Vβ also includes FRβ1 as shown in SEQ ID NO:11, FRβ3 as shown in SEQ ID NO:13, and FRβ4 as shown in SEQ ID NO:
14.
3. The TCR or antigen-binding fragment thereof according to claim 1 or 2, wherein: The Vβ comprises a sequence as shown in SEQ ID NO: 16 or a variant thereof, wherein the variant has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity compared to SEQ ID NO: 16, and comprises CDRβ1-CDRβ3 as shown in SEQ ID NOs: 4-6; preferably, the variant further comprises FRβ2 as shown in SEQ ID NO: 12; Preferably, the variant comprises one or several (eg 1, 2, 3, 4 or 5) amino acid substitutions (eg conservative substitutions) in FRβ1, FRβ3 and / or FRβ4 compared to SEQ ID NO:
16.
4. The TCR or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein: The Vα includes FRα1 as shown in SEQ ID NO:7, FRα2 as shown in SEQ ID NO:8, FRα3 as shown in SEQ ID NO:9, and FRα4 as shown in SEQ ID NO:
10.
5. The TCR or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein: The Vα comprises the sequence shown in SEQ ID NO: 15 or a variant thereof, wherein the variant has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 15, and comprises CDRα1-CDRα3 shown in SEQ ID NOs: 1-3; Preferably, the variant comprises one or several (eg 1, 2, 3, 4 or 5) amino acid substitutions (eg conservative substitutions) in FRα1, FRα2, FRα3 and / or FRα4 compared to SEQ ID NO:
15.
6. The TCR or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein: The Vα comprises the sequence shown in SEQ ID NO:15, and / or the Vβ comprises the sequence shown in SEQ ID NO:
16.
7. The TCR or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein: The TCR is a full-length TCR, a soluble TCR or a single-chain TCR.
8. The TCR or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein: The TCR is either soluble or membrane bound.
9. A conjugate comprising the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 and an effector portion conjugated thereto; Preferably, the TCR or antigen-binding fragment thereof is soluble.
10. A fusion protein comprising the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 and another peptide or protein; Preferably, the TCR or antigen-binding fragment thereof is soluble.
11. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the TCR or antigen-binding fragment thereof or the α chain variable region and / or β chain variable region as described in any one of claims 1 to 8, or comprising a nucleotide sequence encoding the fusion protein as described in claim 10.
12. A vector comprising the isolated nucleic acid molecule of claim 11; Preferably, the vector comprises a nucleotide sequence encoding the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 or its α chain variable region and / or β chain variable region; Preferably, the vector comprises a nucleotide sequence encoding the fusion protein of claim 10; Preferably, the vector is a viral vector, such as a lentiviral vector, a retroviral vector, an adenoviral vector, an adeno-associated viral vector or a baculoviral vector.
13. A host cell comprising the isolated nucleic acid molecule of claim 11, or the vector of claim 12; Preferably, the host cell comprises a nucleotide sequence encoding the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 or its α chain variable region and / or β chain variable region; Preferably, the host cell comprises a nucleotide sequence encoding the fusion protein of claim 10; Preferably, the host cell comprises Escherichia coli, yeast, insect cells, or mammalian cells.
14. A method for preparing the TCR or its antigen binding fragment according to any one of claims 1 to 8, or the fusion protein according to claim 10, comprising culturing the host cell according to claim 13 under conditions that allow protein expression, and recovering the TCR or its antigen binding fragment, or the fusion protein from the cultured host cell culture.
15. A modified immune cell expressing the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 on the cell surface; Preferably, the modified immune cell comprises a nucleotide sequence encoding the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8; Preferably, the immune cells are lymphocytes; Preferably, the immune cells are selected from T cells (such as αβT cells, γδT cells or iPSC-induced T cells), tumor infiltrating lymphocytes (TILs), natural killer (NK) cells, natural killer T (NKT) cells, or any combination thereof; Preferably, the modified immune cells are T cell receptor engineered T cells (TCR-T).
16. A method for preparing the engineered immune cell of claim 15, comprising: (1) Providing immune cells from the subject; (2) introducing a nucleotide sequence encoding the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 (e.g., a vector comprising the nucleotide sequence) into the immune cell described in step (1) to obtain an immune cell expressing the TCR or antigen-binding fragment thereof; Preferably, in step (1), the immune cells are pretreated; the pretreatment includes sorting, activation and / or proliferation of immune cells; Preferably, the pretreatment comprises contacting the immune cells with one or more selected from anti-CD3 antibodies, anti-CD28 antibodies, IL-2 and IL-15, thereby stimulating the immune cells and inducing their proliferation, thereby generating pretreated immune cells.
17. A pharmaceutical composition comprising the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8, the conjugate according to claim 9, the fusion protein according to claim 10, the isolated nucleic acid molecule according to claim 11, the vector according to claim 12, the host cell according to claim 13, or the modified immune cell according to claim 15; and a pharmaceutically acceptable carrier and / or excipient; Preferably, the pharmaceutical composition further comprises an additional therapeutic agent, such as an anti-tumor agent or an immunopotentiator; Preferably, the anti-tumor agent is selected from alkylating agents, mitotic inhibitors, anti-tumor antibiotics, antimetabolites, topoisomerase inhibitors, tyrosine kinase inhibitors, radionuclide agents, radiosensitizers, anti-angiogenic agents, cytokines, immune checkpoint inhibitors (e.g., PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, LAG-3 antibody or TIM3 antibody); Preferably, the immunoenhancer is selected from immunostimulatory antibodies (e.g., anti-CD3 antibodies, anti-CD28 antibodies, anti-CD40L (CD154) antibodies, anti-41BB (CD137) antibodies, anti-OX40 antibodies, anti-GITR antibodies, or any combination thereof) or immunostimulatory cytokines (e.g., IL-2, IL-3, IL-12, IL-15, IL-18, IFN-γ, IL-10, TGF-β, GM-CSF, or any combination thereof).
18. Use of the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8, the conjugate according to claim 9, the fusion protein according to claim 10, the isolated nucleic acid molecule according to claim 11, the vector according to claim 12, the host cell according to claim 13, or the modified immune cell according to claim 15, or the pharmaceutical composition according to claim 17 in the preparation of a medicament for preventing or treating a tumor in a subject; Preferably, the tumor is a NY-ESO-1 positive tumor; Preferably, the tumor is a solid tumor; preferably, the tumor is selected from myxoid liposarcoma (such as myxoid round cell liposarcoma), synovial sarcoma (such as neuroblastoma synovial sarcoma), melanoma, multiple myeloma, ovarian cancer, renal cell carcinoma, non-small cell lung cancer, bladder cancer, esophageal cancer, liver cancer, head and neck cancer, prostate cancer, breast cancer; Preferably, the subject is a human; Preferably, the subject is HLA-A*02:01 positive; Preferably, the TCR or its antigen-binding fragment, conjugate, fusion protein, nucleic acid molecule or vector or host cell, modified immune cell, or pharmaceutical composition is administered in combination with another therapeutic agent, such as simultaneously, separately or sequentially; preferably, the other therapeutic agent is an immunostimulatory agent or an anti-tumor agent.
19. A method for preventing or treating a tumor in a subject, the method comprising administering to a subject in need thereof an effective amount of the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8, the conjugate according to claim 9, the fusion protein according to claim 10, the isolated nucleic acid molecule according to claim 11, the vector according to claim 12, the host cell according to claim 13, or the modified immune cell according to claim 15, or the pharmaceutical composition according to claim 17; Preferably, the tumor is a NY-ESO-1 positive tumor; Preferably, the tumor is a solid tumor; preferably, the tumor is selected from myxoid liposarcoma (such as myxoid round cell liposarcoma), synovial sarcoma (such as neuroblastoma synovial sarcoma), melanoma, multiple myeloma, ovarian cancer, renal cell carcinoma, non-small cell lung cancer, bladder cancer, esophageal cancer, liver cancer, head and neck cancer, prostate cancer, breast cancer; Preferably, the subject is a human; Preferably, the subject is HLA-A*02:01 positive; Preferably, the method further comprises administering to the subject an additional therapeutic agent, such as an immunopotentiator or an anti-tumor agent; Preferably, the method comprises: (1) Providing immune cells required by the subject; (2) introducing a nucleotide sequence encoding the TCR or antigen-binding fragment thereof according to any one of claims 1 to 8 into the immune cells described in step (1) to obtain immune cells expressing the TCR or antigen-binding fragment thereof on the surface; (3) administering the immune cells obtained in step (2) to the subject; Preferably, the immune cells are lymphocytes; Preferably, the immune cells are selected from T cells (eg, αβT cells, γδT cells or iPSC-induced T cells), tumor infiltrating lymphocytes (TILs), natural killer (NK) cells, natural killer T (NKT) cells, or any combination thereof.
Citation Information
Patent Citations
Gene modification gamma delta T cell
CN109777778A
T cell modification
CN113166778A
Modified t cell receptors and related materials and methods
US20100034834A1
